Neglected Tropical Diseases Diagnosis Market Size, Share, Growth, and Industry Analysis, By Type (Conventional Method, Molecular/Modern Method), By Application (Clinical Labs, Hospitals /Clinics, Home Healthcare), Regional Insights and Forecast to 2034

Neglected Tropical Diseases Diagnosis Market Overview

The Neglected Tropical Diseases Diagnosis Market size was valued at USD 6713.69 million in 2025 and is expected to reach USD 9189.71 million by 2034, growing at a CAGR of 3.5% from 2025 to 2034.

The Neglected Tropical Diseases Diagnosis Market is expanding due to the increasing burden of more than 20 WHO-recognized neglected tropical diseases affecting over 1.49 billion people globally in 2025. Diagnostic demand has increased across polymerase chain reaction testing, rapid antigen kits, immunoassays, and microscopy systems, with molecular diagnostics accounting for nearly 42% of advanced infectious disease screening installations in tropical healthcare programs.

The United States Neglected Tropical Diseases Diagnosis Market is witnessing increasing testing volumes because nearly 12 million people in the country are estimated to live with neglected parasitic infections. Public health agencies expanded tropical disease surveillance activities across 35 states between 2023 and 2025. Molecular diagnostic usage in U.S. tropical disease laboratories surpassed 48% of total infectious disease testing workflows, while hospital-based tropical disease panels increased by 27% during 2024.

• 

  Download Free sample to learn more about this report.

Key Findings

• Key Market Driver:Rising tropical disease prevalence contributed to more than 61% growth in infectious disease screening programs, while rapid diagnostic adoption increased by 46%, molecular testing penetration reached 42%, and public health-supported disease surveillance expanded across 57% of endemic healthcare systems during 2024.
• Major Market Restraint:Nearly 49% of low-income healthcare facilities continue facing limited laboratory infrastructure, while 41% of endemic regions report shortages of trained diagnostic professionals, 36% experience delayed reagent supply chains, and 29% of rural clinics still lack advanced molecular screening equipment.
• Emerging Trends:Point-of-care testing utilization exceeded 38% across tropical healthcare systems, AI-supported diagnostic interpretation increased by 32%, multiplex infectious disease panel deployment rose by 44%, and smartphone-connected rapid testing solutions expanded by 28% in community disease screening initiatives.
• Regional Leadership:Africa accounted for approximately 39% of neglected tropical disease diagnostic demand, Asia-Pacific represented nearly 34%, North America contributed 14%, Europe captured 10%, and Middle East & Africa cross-border infectious disease collaborations expanded by 31% during 2025.
• Competitive Landscape:The top five diagnostic manufacturers controlled nearly 54% of global infectious disease diagnostic installations, while automated immunoassay systems represented 36% of commercial testing platforms and rapid diagnostic kit suppliers increased tropical disease-focused product launches by 29% between 2023 and 2025.
• Market Segmentation:Molecular and modern diagnostic methods contributed nearly 52% of advanced testing adoption, while conventional microscopy-based systems retained 48% share in rural screening programs. Hospitals and clinics represented 46% of total testing demand, clinical laboratories accounted for 39%, and home healthcare contributed 15%.
• Recent Development:Between 2023 and 2025, more than 37 new tropical disease diagnostic kits received public health approvals globally, multiplex PCR panel launches increased by 34%, portable diagnostic analyzer deployment rose by 26%, and AI-integrated infectious disease interpretation software installations expanded by 22%.

Neglected Tropical Diseases Diagnosis Market Latest Trends

The Neglected Tropical Diseases Diagnosis Market is experiencing substantial transformation due to increased molecular screening adoption, rising infectious disease surveillance, and growing demand for decentralized testing platforms. More than 1 billion individuals remain affected by neglected tropical diseases worldwide, creating strong demand for rapid diagnostic tools capable of delivering results within 15 to 30 minutes. Multiplex molecular testing systems gained nearly 44% installation growth across public health laboratories during 2024, while portable PCR analyzers expanded by 31% in remote healthcare environments.

Artificial intelligence integration is becoming a notable trend across infectious disease diagnostics. AI-assisted microscopy systems improved parasite identification accuracy by over 28% in pilot programs conducted across endemic countries. Smartphone-connected diagnostic readers increased field-level screening efficiency by 33%, especially in dengue, leishmaniasis, and schistosomiasis programs. Automated immunoassay analyzers now represent approximately 36% of laboratory-based tropical disease testing systems.

Neglected Tropical Diseases Diagnosis Market Dynamics

DRIVER

Rising demand for rapid infectious disease screening programs

The increasing prevalence of dengue, leishmaniasis, Chagas disease, lymphatic filariasis, and schistosomiasis is significantly supporting growth in the Neglected Tropical Diseases Diagnosis Market. More than 1.49 billion individuals required intervention and monitoring programs in 2025, while over 867 million people underwent treatment-linked disease screening initiatives during 2023. Rapid diagnostic testing demand increased by 46% because healthcare agencies are prioritizing early-stage disease identification.

Public health organizations expanded laboratory capacity across more than 112 endemic countries during 2024. Portable molecular diagnostic devices achieved 31% penetration growth in rural healthcare settings, while automated immunoassay adoption increased by 26% in infectious disease laboratories. Government-backed tropical disease surveillance campaigns also expanded by 37%, resulting in stronger procurement activity for diagnostic kits, reagents, and automated laboratory systems.

RESTRAINT

Limited laboratory infrastructure in underdeveloped regions

Despite rising testing demand, healthcare infrastructure limitations remain a major barrier in the Neglected Tropical Diseases Diagnosis Market. Nearly 49% of healthcare facilities in low-income endemic countries lack standardized molecular testing systems, while 36% continue experiencing irregular reagent supplies. Skilled diagnostic personnel shortages affect approximately 41% of tropical disease laboratories, reducing testing accuracy and turnaround efficiency.

Rural healthcare access remains limited, with nearly 29% of endemic communities located more than 50 kilometers away from advanced diagnostic facilities. Microscopy remains dominant in several countries because modern PCR systems involve maintenance requirements exceeding the operational capacity of many small laboratories. Cold-chain logistics challenges impact approximately 24% of rapid diagnostic kit distribution networks, while funding gaps delay modernization efforts across infectious disease testing infrastructure.

OPPORTUNITY

Expansion of point-of-care and home-based diagnostics

The rising demand for decentralized healthcare services is creating strong opportunities in the Neglected Tropical Diseases Diagnosis Market. Point-of-care diagnostic systems represented nearly 38% of screening procedures conducted in remote regions during 2024. Portable antigen testing kits reduced disease detection time by more than 60% compared with conventional laboratory workflows. Smartphone-enabled diagnostic devices increased field screening coverage by 28%, particularly in vector-borne disease monitoring campaigns.

Home healthcare infectious disease testing programs also expanded because over 44% of tropical disease screening initiatives are now incorporating mobile health support technologies. Multiplex diagnostic systems capable of detecting 3 to 5 pathogens simultaneously increased adoption by 34% across regional hospitals and public health laboratories. International healthcare partnerships funded more than 140 diagnostic innovation projects between 2023 and 2025, creating favorable opportunities for manufacturers developing low-cost and rapid tropical disease testing platforms.

CHALLENGE

Variability in diagnostic accuracy and disease surveillance

Diagnostic inconsistency remains a major challenge in the Neglected Tropical Diseases Diagnosis Market because tropical diseases often present overlapping symptoms and require region-specific screening approaches. False-negative rates for certain parasitic diseases remain above 18% in low-resource settings due to poor sample handling and limited laboratory quality control. Approximately 27% of endemic countries still lack integrated national surveillance systems capable of real-time disease monitoring.

Cross-reactivity in antibody-based tests continues affecting diagnostic precision for dengue and leishmaniasis screening programs. More than 30% of rural laboratories still depend on manual microscopy methods with limited automation support, increasing variability in test interpretation. Climate-related vector expansion has also complicated disease mapping activities across tropical and subtropical regions, while fragmented data reporting systems continue affecting outbreak forecasting accuracy.

• 

  Download Free sample to learn more about this report.

Neglected Tropical Diseases Diagnosis Market Segmentation Analysis

The Neglected Tropical Diseases Diagnosis Market is segmented by type and application, with molecular and modern methods gaining stronger adoption due to improved sensitivity rates exceeding 90% in several infectious disease panels. Conventional methods continue maintaining broad accessibility across rural healthcare systems because microscopy-based diagnosis remains operational in nearly 48% of endemic laboratories. Hospitals and clinics account for approximately 46% of testing demand due to increasing inpatient infectious disease management, while clinical laboratories contribute nearly 39% because centralized testing volumes continue rising. Home healthcare diagnostics represent around 15% of market activity, supported by mobile health monitoring and portable antigen testing solutions. Increased deployment of multiplex screening systems and rapid diagnostic technologies is strengthening segmentation diversity.

By Type

Conventional Method

Conventional diagnostic methods continue representing approximately 48% of the Neglected Tropical Diseases Diagnosis Market due to widespread use of microscopy, serology, and culture-based techniques across low-resource healthcare systems. Microscopy remains the primary diagnostic method in more than 60 endemic countries because operational costs are nearly 35% lower compared with advanced molecular systems. Conventional blood smear testing continues supporting malaria, filariasis, and trypanosomiasis screening programs in over 70% of rural laboratories. Serological assays account for nearly 32% of conventional testing procedures because of accessibility and lower training requirements. Public health campaigns distributed more than 18 million microscopy consumables during 2024.

Molecular/Modern Method

Molecular and modern diagnostic methods account for nearly 52% of advanced Neglected Tropical Diseases Diagnosis Market adoption due to high sensitivity, faster turnaround time, and multiplex testing capabilities. Polymerase chain reaction systems achieved more than 42% penetration across infectious disease reference laboratories in 2025. Real-time PCR testing demonstrates sensitivity rates above 92% for dengue and leishmaniasis screening. Rapid antigen diagnostics contributed approximately 47% of field-level disease surveillance activities during outbreak response programs. Automated immunoassay systems increased installation rates by 26% across tertiary healthcare centers.

By Application

Clinical Labs

Clinical laboratories represent approximately 39% of the Neglected Tropical Diseases Diagnosis Market because centralized infectious disease screening volumes continue increasing globally. More than 55% of molecular diagnostic procedures for tropical diseases are performed in regional and national reference laboratories. Automated immunoassay analyzers now support over 33% of laboratory workflows for dengue and Chagas disease testing. Laboratory sample throughput improved by nearly 24% following integration of automated nucleic acid extraction systems. Public health surveillance collaborations expanded diagnostic reporting efficiency by 29% across centralized laboratory networks.

Hospitals /Clinics

Hospitals and clinics account for approximately 46% of Neglected Tropical Diseases Diagnosis Market demand because inpatient infectious disease management and emergency outbreak response testing continue expanding. More than 62% of hospitalized dengue and leishmaniasis cases require laboratory confirmation through rapid antigen or molecular diagnostics. Hospital-based tropical disease screening programs increased by 27% during 2024, while emergency department infectious disease testing volumes rose by 19%. Portable diagnostic systems reduced average patient screening time from 48 hours to less than 8 hours in tertiary healthcare settings. Nearly 40% of urban hospitals in endemic regions integrated multiplex PCR testing panels capable of identifying 3 to 6 pathogens simultaneously. Clinics also expanded community disease surveillance programs by 23% through mobile diagnostic outreach initiatives.

Home Healthcare

Home healthcare contributes nearly 15% of the Neglected Tropical Diseases Diagnosis Market due to increasing demand for decentralized disease monitoring and self-testing technologies. Smartphone-enabled rapid testing kits expanded by 28% during 2025, especially for dengue surveillance and follow-up screening programs. Portable diagnostic readers now support home-based antigen testing with sensitivity levels exceeding 85% in selected tropical diseases. More than 44% of mobile health initiatives incorporated home diagnostic monitoring tools in remote communities. Telehealth integration improved reporting efficiency by 31% for community infectious disease management programs.

• 

  Download Free sampleto learn more about this report.

Neglected Tropical Diseases Diagnosis Market Regional Outlook

North America

North America accounts for approximately 14% of the Neglected Tropical Diseases Diagnosis Market due to strong infectious disease surveillance infrastructure, advanced laboratory capabilities, and rising imported tropical disease cases. The United States represents nearly 82% of the regional market because over 12 million people are estimated to live with neglected parasitic infections. Imported dengue screening volumes increased by more than 33% during 2024, while Chagas disease testing expanded by 21% across urban diagnostic centers.

Molecular diagnostics dominate the North American market, representing nearly 58% of all tropical disease testing procedures. Real-time PCR systems are deployed across more than 220 specialized tropical medicine clinics and public health laboratories. Automated immunoassay analyzers account for approximately 39% of hospital-based infectious disease testing workflows. Public health monitoring activities expanded across 35 U.S. states between 2023 and 2025 due to climate-driven mosquito population growth.

Europe

Europe represents nearly 10% of the Neglected Tropical Diseases Diagnosis Market because imported tropical diseases, migration-linked screening programs, and international public health partnerships continue expanding. More than 40 European infectious disease laboratories upgraded molecular screening capabilities between 2023 and 2025. Imported dengue case monitoring increased by 27% across Western Europe during 2024 due to higher international travel volumes.

PCR-based testing accounts for approximately 54% of neglected tropical disease diagnostics across Europe. Automated nucleic acid extraction systems improved laboratory productivity by 23%, while multiplex testing platforms capable of detecting 4 to 7 pathogens simultaneously increased adoption by 28%. Public health laboratories in France, Germany, Italy, and Spain expanded vector-borne disease monitoring programs across more than 120 surveillance sites.

Asia-Pacific

Asia-Pacific accounts for approximately 34% of the Neglected Tropical Diseases Diagnosis Market due to high endemic disease prevalence, large population exposure, and expanding healthcare infrastructure. India, China, Indonesia, Thailand, and the Philippines collectively represent more than 63% of regional diagnostic demand. The region continues experiencing substantial burdens of dengue, lymphatic filariasis, soil-transmitted helminthiasis, and leishmaniasis.

More than 700 million people across Asia-Pacific remain at risk of tropical infectious diseases, supporting continuous expansion of diagnostic screening programs. Rapid diagnostic kits account for approximately 49% of field-level testing procedures because decentralized healthcare systems require portable and low-cost solutions. Molecular diagnostic adoption increased by 37% between 2023 and 2025 across tertiary healthcare centers.

Middle East & Africa

Middle East & Africa represents a critical region in the Neglected Tropical Diseases Diagnosis Market because Africa accounts for approximately 39% of global neglected tropical disease burden. More than 600 million individuals across Sub-Saharan Africa remain exposed to diseases such as schistosomiasis, onchocerciasis, and lymphatic filariasis. Rapid diagnostic testing adoption increased by 36% between 2023 and 2025 across community healthcare programs.

Portable and battery-operated diagnostic systems account for nearly 41% of field-based screening procedures due to infrastructure limitations in remote healthcare settings. Public health organizations expanded mobile laboratory deployments by 27%, while international disease elimination partnerships supported diagnostic screening in over 30 African countries. Molecular testing penetration remains below 30% in several regions, creating substantial opportunities for healthcare modernization.

List of Top Neglected Tropical Diseases Diagnosis Companies

• Abbott Laboratories
• Beckman Coulter/Danaher
• Bio-Rad Laboratories, Inc.
• Life Technology
• Novartis Diagnostics., Ltd.
• Ortho-Clinical Diagnostics
• Premier Medical Corporation Ltd.
• Siemens Healthcare
• Wako Chemicals, Inc.

List of Top 2 Neglected Tropical Diseases Diagnosis Companies

• Abbott Laboratories – Holds one of the leading shares in neglected tropical diseases rapid diagnostics, with more than 30% penetration in selected infectious disease screening programs and a 24% increase in portable diagnostic analyzer deployment between 2023 and 2025.
• Siemens Healthcare – Accounts for approximately 18% of advanced infectious disease laboratory installations, while automated immunoassay workflow integration improved laboratory throughput efficiency by nearly 27% in tropical disease diagnostic centers.

Investment Analysis and Opportunities

The Neglected Tropical Diseases Diagnosis Market is attracting increasing investment due to rising disease surveillance requirements and expansion of public healthcare infrastructure. More than 140 infectious disease diagnostic innovation projects received institutional support during 2025, while global health partnerships expanded tropical disease screening programs across 112 countries. Investments in portable molecular diagnostics increased by 31% between 2023 and 2025 because rural healthcare systems require compact and low-maintenance testing platforms.Point-of-care diagnostic systems represent a major investment opportunity, with rapid testing adoption exceeding 38% across low-resource healthcare settings.

Asia-Pacific and Africa remain the largest investment regions because they collectively account for over 70% of neglected tropical disease burden. Government-backed elimination programs increased infectious disease screening budgets in more than 20 endemic countries during 2024. International health organizations also supported laboratory modernization projects aimed at improving molecular testing penetration above current levels.Home healthcare diagnostics present another opportunity because mobile health adoption increased by 44% in remote tropical disease monitoring programs. Smartphone-connected testing devices expanded by 28%, while telehealth-integrated diagnostic reporting systems improved disease management efficiency by 31%.

New Product Development

New product development in the Neglected Tropical Diseases Diagnosis Market is focused on faster turnaround times, higher sensitivity, and portable testing functionality. More than 37 tropical disease diagnostic products entered public health evaluation programs between 2023 and 2025. Multiplex PCR systems capable of detecting dengue, chikungunya, Zika virus, and malaria simultaneously increased by 34% in infectious disease laboratories.Portable molecular analyzers weighing less than 5 kilograms gained strong adoption due to their ability to deliver results within 30 minutes. Battery-powered diagnostic systems capable of continuous operation for over 12 hours improved remote healthcare testing efficiency by 22%.

Rapid antigen testing innovation is another important development area. Sensitivity rates for next-generation rapid diagnostic kits exceeded 90% in several dengue and leishmaniasis pilot programs. Smartphone-compatible diagnostic readers improved result interpretation consistency by 25%, while cloud-connected disease reporting platforms strengthened outbreak response coordination.Manufacturers are also focusing on reagent stability improvements. Heat-resistant diagnostic consumables capable of remaining stable above 40 degrees Celsius reduced cold-chain dependency by nearly 20% in tropical environments.

Five Recent Developments (2023-2025)

1. In 2025, multiple infectious disease manufacturers expanded multiplex PCR panel capabilities to identify up to 8 tropical pathogens simultaneously, improving laboratory testing efficiency by nearly 33%.
2. During 2024, portable molecular diagnostic analyzer deployment increased by 31% across remote healthcare programs in Africa and Asia-Pacific, supporting faster outbreak response activities.
3. In 2023, AI-assisted microscopy software improved parasite detection accuracy by approximately 28% in pilot tropical disease laboratories operating in endemic regions.
4. Between 2023 and 2025, more than 37 neglected tropical disease diagnostic products entered public health validation or approval programs, including rapid antigen kits and integrated molecular systems.
5. In 2024, cloud-connected disease surveillance platforms expanded implementation across over 48% of infectious disease reference laboratories, improving real-time outbreak monitoring and reporting efficiency.

Report Coverage of Neglected Tropical Diseases Diagnosis Market

The Neglected Tropical Diseases Diagnosis Market Report provides comprehensive analysis of infectious disease diagnostic technologies, testing infrastructure, application trends, regional demand patterns, and competitive market developments across global healthcare systems. The report evaluates more than 20 neglected tropical diseases, including dengue, leishmaniasis, Chagas disease, schistosomiasis, lymphatic filariasis, and onchocerciasis. More than 1.49 billion people currently require neglected tropical disease interventions, making diagnostic accessibility and surveillance capacity essential healthcare priorities.

The report covers conventional and modern diagnostic methods, including microscopy, serology, polymerase chain reaction systems, rapid antigen testing, automated immunoassays, and AI-assisted diagnostic technologies. Molecular and modern testing methods currently account for approximately 52% of advanced infectious disease diagnostics, while conventional methods continue supporting nearly 48% of screening activity in low-resource healthcare systems.Application analysis includes hospitals and clinics, clinical laboratories, and home healthcare diagnostics. Hospitals and clinics represent nearly 46% of market demand because inpatient infectious disease management and emergency outbreak response testing continue increasing.